Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Alganelle operates a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The current prosecution status includes 1 pending office action. This activity is confined to 1 distinct art unit, reflecting a specialized technical scope for the pending application. The portfolio is currently being reviewed by 1 distinct examiner, AFREMOVA, VERA. Because AFREMOVA, VERA is the busiest examiner with 1 busiest examiner pending, the outcome of the current prosecution cycle rests entirely with this individual.
For practitioners, the fact that there is only 1 pending office action suggests a streamlined or early-stage portfolio. The reliance on 1 distinct examiner highlights the importance of tailored communication with the assigned art unit. Every response must be carefully crafted, as there are no other active matters to balance the portfolio's progress. This concentration means that the company's immediate patent prospects are shaped by a single individual's interpretation of the claims and prior art. The lack of examiner diversity means there is no internal baseline for comparing examiner behavior within this portfolio. Consequently, the immediate success of the company's patent strategy depends on the interactions with AFREMOVA, VERA.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AFREMOVA, VERA | 1 | 50.5% | +29.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17802572 | RECOMBINANT MICROALGAE ABLE TO PRODUCE KTTKS PEPTIDES, POLYPEPTIDES, OR PROTEINS AND THEIR DERIVATIVES AND ASSOCIATED METHOD AND USES THEREOF | AFREMOVA, VERA | — |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17802572 | RECOMBINANT MICROALGAE ABLE TO PRODUCE KTTKS PEPTIDES, POLYPEPTIDES, OR PROTEINS AND THEIR DERIVATIVES AND ASSOCIATED METHOD AND USES THEREOF | AFREMOVA, VERA | 1653 | §103 | Final Rejection | — | Pending | Aug 26, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial